{"nctId":"NCT01059344","briefTitle":"Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis","startDateStruct":{"date":"2009-11"},"conditions":["Ulcerative Colitis"],"count":281,"armGroups":[{"label":"Mesalamin","type":"EXPERIMENTAL","interventionNames":["Drug: Mesalamin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Mesalamin"]}],"interventions":[{"name":"Mesalamin","otherNames":["Asacol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n(1) Male or non-pregnant, non-lactating females, 18 years of age or older. (2) Documented diagnosis of UC with disease extending at least 15 cm from the anal verge.\n\n(3) Active UC defined by:\n\n(a) modified UC-DAI score of 4-10 with (b) sigmoidoscopy component score ≥ 2 and (c) rectal bleeding component score ≥ 1 (4) Ability of subject to participate fully in all aspects of this clinical trial.\n\n(5) Written informed consent must be obtained and documented.\n\nExclusion Criteria:\n\n1. Severe UC defined by the following criteria:\n\n   ³6 bloody stools daily with one or more of the following:\n   1. oral temperature \\> 37.8°C or \\> 100.0°F\n   2. pulse \\> 90/min\n   3. hemoglobin \\< 10 g/dL\n2. Previously failed treatment with a mesalazine dose of \\> 2.0 g/day.\n3. Current relapse lasting \\> 6 weeks in the opinion of the investigator.\n4. Treatment with 5-ASA at a dose of \\>2.0g/day within 1 week prior to randomisation\n5. Treatment with systemic or rectal steroids within 4 weeks prior to randomization.\n6. Treatment with immunosuppressants within 6 weeks prior to randomization.\n7. Treatment with infliximab or other biologics within 3 months prior to randomization.\n8. Treatment with systemic antibiotics for UC within 7 days prior to randomization.\n9. Treatment with probiotics within 7 days prior to randomization.\n10. Treatment with anti-diarrheals within 7 days prior to randomization.\n11. Treatment with nicotine patch within 7 days prior to randomization.\n12. Received any investigational drug within 30 days prior to randomization.\n13. History of colectomy or partial colectomy.\n14. History of definite dysplasia in colonic biopsies.\n15. Crohn's disease.\n16. Known bleeding disorders.\n17. Immediate or significant risk of toxic megacolon.\n18. Hypersensitivity to salicylates, aspirin, sulfasalazine or 5-ASA.\n19. Serum creatinine \\> 1.5 times the upper limit of the normal range.\n20. AST, ALT, total bilirubin or alkaline phosphatase \\> 2 times the upper limit of the normal range.\n21. Serious underlying disease other than UC which in the opinion of the investigator may interfere with the subject's ability to participate fully in the study.\n22. History of alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures.\n23. Stools positive for clostridium difficile.\n24. Pregnant or lactating women.\n25. Prior enrolment in the current study and had received study treatment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"To Achieve Clinical Remission in Subjects With Active Ulcerative Colitis (UC).","description":"Clinical remission defined as stool frequency score of 0, rectal bleeding score of 0, no urgency","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Remission","description":"Clinical remission defined as a score of 0 for stool frequency, 0 for rectal bleeding and no urgency","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Endoscopic Remission","description":"Endoscopic remission is defined as a sigmoidoscopy score of 1 or less","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Endoscopic Remission","description":"Endoscopic remission is defined as a sigmoidoscopy score of 1 or less","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement","description":"Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement","description":"Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]}]},{"type":"POST_HOC","title":"To Achieve Clinical Remission in the Patient Population Confirmed by the Central Reader","description":"Clinical Remission, defined as stool frequency score of 0, rectal bleeding score of 0 and absence of urgency in subjects with adequate disease extent at baseline confirmed by central reading.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":140},"commonTop":["Colitis ulcerosa","Anaemia","Monozytopenia"]}}}